Thomas Holm Pedersen - Crunchbase Person Profile
aging • The Journal of Frailty & Aging
Novo A/S Novo Seeds. Letter from the CEO SYNLAB. Novo Ventures - PDF Free Download
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
aging • The Journal of Frailty & Aging
HITTA ER ET A UN AMI TA ON HI HA UT ME AT THE
dkbio17 hashtag on Twitter
State of the Union Novo Holdings
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
Dansk Biotek by partnermedier - issuu
Thomas Holm Pedersen - Crunchbase Person Profile
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
NMD Pharma
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
PDF) The Impact of Oligofructose on Stimulation of Gut Hormones, Appetite Regulation and Adiposity
Denmark in New York в Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
WO2016202341A1 - Compounds for use in treating neuromuscular disorders - Google Patents
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
PDF) Development and evaluation of liposomal formulation containing nimodipine on anxiolytic activity in mice
NMD Pharma | The Org
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
NMD Pharma A/S | LinkedIn
Thomas H. Pedersen - CEO at NMD Pharma | The Org
